Noblewell   Report issue

For profit Phase 3
Founded: Warsaw Poland (2012)

Organization Overview

First Clinical Trial
2013
NCT01939912
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Noblewell

Active Ingredients

Drugs in Phase 3 Trials (1)

amantadine (symmetrel) (1 trial)

Drugs in Other Trials (1)

adenosine (Adenocard) (1 trial)

Indications

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2